세계의 자궁경부암 치료 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 치료법별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Cervical Cancer Treatment Market Size, Share & Trends Analysis Report By Type (Squamous Cell Carcinoma), By Treatment, By End-use (Hospital & Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

자궁경부암 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 자궁경부암 치료 세계 시장 규모는 2024년부터 2030년까지 연평균 복합 성장률(CAGR) 5.4%를 기록하여 2030년에는 117억 4,000만 달러에 달할 것으로 예상됩니다.

치료 보급률 증가와 질병 유병률 증가는 향후 몇 년동안 시장 성장을 견인할 것으로 예상되며, HPV는 주로 성행위를 통해 감염되지만 경구피임약, 여러 성 파트너, 흡연, HIV 감염 등 다른 요인에 의해 발병할 수도 있습니다. 있으며, 그 중 13종은 고위험군 또는 암으로 발전합니다. 편평상피암이 가장 많으며 전체의 85% 정도를 차지합니다.

편평상피암과 선암의 감별은 현미경으로 관찰한 조직 사진을 기준으로 합니다. 자궁경부 선 편평상피암은 드물고 편평상피 조직과 선 조직이 혼합되어 있습니다. 자궁경부암의 치료법은 크게 예방과 치료로 나뉩니다. 예방에는 HPV에 대한 백신이 있습니다. 현재 가다실과 서바릭스 두 가지 백신이 시판되고 있습니다. 치료 옵션으로는 아바스틴과 같은 생물학적 제제와 토포테칸, 시스플라틴, 브레오마이신, 플루오로라실, 파클리탁셀, 카보플라틴, 독소루비신과 같은 제네릭 의약품이 있습니다. 효능을 개선하고 비용을 절감하는 표적 치료제의 개발은 여전히 이 시장의 주요 미충족 수요로 남아 있습니다. 그럼에도 불구하고 자궁경부암을 포함한 종양학 연구개발에 대한 집중이 확대되고 있는 것은 이 시장의 미래가 유망하다는 것을 보여줍니다.

자궁경부암 치료 시장 보고서 하이라이트

• 편평상피암 유형이 2023년 71.1%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다. 이러한 성장은 고위험군 인유두종 바이러스(HPV) 아형(주로 HPV 16과 18)의 지속적인 감염이 대부분의 사례를 차지했기 때문입니다.
• 화학요법 치료는 2023년 33.9%로 가장 큰 매출 점유율을 차지하며 시장을 주도했습니다. 이러한 성장은 자궁경부 선암에 대한 치료 옵션을 크게 강화한 약물 개발의 발전으로 인한 것입니다.
• 병원 및 클리닉 부문은 2023년 65.0%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다. 이러한 성장은 표적 치료, 방사선 치료, 면역 요법, 최소 침습 수술 및 기타 여러 가지 방법을 포함하여 병원 및 클리닉에서 제공하는 전달 절차가 강화되었기 때문입니다.
• 북미 자궁경부암 치료 시장은 2023년 39.4%의 가장 큰 매출 점유율을 차지하며 세계 시장을 장악했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 자궁경부암 치료 시장 변수, 동향, 범위

• 시장 서론/계통 전망
• 시장 규모와 성장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 자궁경부암 치료 시장 분석 툴
  • Porter의 Five Forces 분석
  • PESTEL 분석

제4장 자궁경부암 치료 시장 : 유형별 추정·동향 분석

• 부문 대시보드
• 자궁경부암 치료 시장 변동 분석 : 유형별, 2023년 및 2030년
• 편평세포암종
• 선암종
• 선편평암종
• 기타

제5장 자궁경부암 치료 시장 : 치료별 추정·동향 분석

• 부문 대시보드
• 자궁경부암 치료 시장 변동 분석 : 치료별, 2023년 및 2030년
• 방사선 치료
• 화학 요법
• 표적 치료
• 면역 치료
• 기타

제6장 자궁경부암 치료 시장 : 최종 용도별 추정·동향 분석

• 부문 대시보드
• 자궁경부암 치료 시장 변동 분석 : 최종 용도별, 2023년 및 2030년
• 병원 및 클리닉
• 외래수술센터(ASC)
• 기타

제7장 자궁경부암 치료 시장 : 지역별 추정·동향 분석

• 자궁경부암 치료 시장 점유율 : 지역별, 2023년 및 2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 남아프리카공화국
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업 분류
• 기업 히트맵 분석
• 기업 개요
  • Merck &Co., Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Eli Lilly and Company.
  • Novartis AG
  • AstraZeneca
  • GSK plc.
  • AbbVie Inc.
  • Johnson &Johnson Services, Inc.

LSH

영문 목차

영문목차

Cervical Cancer Treatment Market Growth & Trends:

The global cervical cancer treatment market size is expected to reach USD 11.74 billion by 2030, registering a CAGR of 5.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased treatment penetration and rising disease incidence are projected to drive the market growth over the next few years. Although, sexually transmitted HPV is a major cause, the disease can also be triggered by other factors, such as oral contraceptives, multiple sexual partners, smoking, and HIV infection. There are more than 100 strains of HPV, 13 of which are high-risk or cancerous. Squamous cell carcinoma is the most common type and it accounts for nearly 85% of the overall cases.

The differentiation between squamous cell carcinoma and adenocarcinoma is based on the histology, as observed under the microscope. Cervical adenosquamous carcinoma is rare, involving a mixture of squamous and glandular tissues. Products for cervical cancer can be broadly classified into prevention and treatment. Preventive options involve vaccines against HPV. Currently, there are two commercial vaccines - Gardasil and Cervarix. Treatment options include biologics, such as Avastin and generics like topotecan, cisplatin, bleomycin, fluorouracil, paclitaxel, carboplatin, and doxorubicin. The development of targeted therapeutics with improved efficacy and reduced cost remains a key unmet need of this market. Nevertheless, expanding focus on the research and development in oncology, including cervical cancer, indicate a promising future for this market.

Cervical Cancer Treatment Market Report Highlights:

• Squamous cell carcinoma type dominated the market and accounted for the largest revenue share of 71.1% in 2023. This growth is attributed to persistent infection with high-risk human papillomavirus (HPV) subtypes, mainly HPV 16 and 18, which account for most cases.
• Chemotherapy treatment led the market and accounted for the largest revenue share of 33.9% in 2023. This growth is attributed to the advancements in drug development that have significantly enhanced treatment options for cervical adenocarcinoma.
• Hospitals & clinics segment dominated the market and accounted for the largest revenue share of 65.0% in 2023. This growth is attributed to the enhanced delivery procedures in hospitals & clinics with offerings such as targeted therapy, radiation therapy, immunotherapy, minimally invasive surgeries, and many other methods.
• The North America cervical cancer treatment market dominated the global market and accounted for the largest revenue share of 39.4% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Cervical Cancer Treatment Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Cervical Cancer Treatment Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Cervical Cancer Treatment Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Cervical Cancer Treatment Market: Type Movement Analysis, USD Million, 2023 & 2030
• 4.3. Squamous Cell Carcinoma
  • 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Adenocarcinoma
  • 4.4.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Adenosquamous Carcinoma
  • 4.5.1. Adenosquamous Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Other Types
  • 4.6.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Cervical Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Cervical Cancer Treatment Market: Treatment Movement Analysis, USD Million, 2023 & 2030
• 5.3. Radiation Therapy
  • 5.3.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. External Beam Radiation Therapy (EBRT)
    • 5.3.2.1. External Beam Radiation Therapy (EBRT) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Brachytherapy
    • 5.3.3.1. Brachytherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Chemotherapy
  • 5.4.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. Cisplatin
    • 5.4.2.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Carboplatin
    • 5.4.3.1. Carboplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Paclitaxel
    • 5.4.4.1. Paclitaxel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4.5. Other Chemotherapeutic Agents
    • 5.4.5.1. Other Chemotherapeutic Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Targeted Therapy
  • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Bevacizumab (Avastin)
    • 5.5.2.1. Bevacizumab (Avastin) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. Other Targeted Therapies
    • 5.5.3.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Immunotherapy
  • 5.6.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Pembrolizumab (Keytruda)
    • 5.6.2.1. Pembrolizumab (Keytruda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. Other Immune Checkpoint Inhibitors
    • 5.6.3.1. Other Immune Checkpoint Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Other Therapies
  • 5.7.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Cervical Cancer Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Cervical Cancer Treatment Market: End Use Movement Analysis, USD Million, 2023 & 2030
• 6.3. Hospitals & Clinics
  • 6.3.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Ambulatory Surgery Centers
  • 6.4.1. Ambulatory Surgery Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Others
  • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Cervical Cancer Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Cervical Cancer Treatment Market Share, By Region, 2023 & 2030, USD Million
• 7.2. North America
  • 7.2.1. North America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. South Africa Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Cervical Cancer Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Merck & Co., Inc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Bristol-Myers Squibb Company
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. F. Hoffmann-La Roche Ltd
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Pfizer Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Eli Lilly and Company.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Novartis AG
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. AstraZeneca
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. GSK plc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. AbbVie Inc.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Johnson & Johnson Services, Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives

관련자료